Source-grounded facts extracted from SUPERNUS PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SUPERNUS PHARMACEUTICALS, INC. shareholders approved To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the Plan. at the 2026-06-18 meeting.
“Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the "Plan") to increase the number of shares available under the Plan. Votes For Votes Against Abstain Broker Non-Votes 41,925,692 5,302,088 7,922 3,073,181”
SUPERNUS PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-18 meeting.
“Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstain Broker Non-Votes 49,882,228 417,336 9,319 0”
SUPERNUS PHARMACEUTICALS, INC. shareholders approved To approve, on a non-binding basis, the compensation paid to our named executive officers. at the 2026-06-18 meeting.
“Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers. Votes For Votes Against Abstain Broker Non-Votes 45,552,633 1,675,355 7,714 3,073,181”
SUPERNUS PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2026-06-18 meeting.
“Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2029. Name Votes For Votes Withheld Broker Non-Votes Frederick M. Hudson 45,058,634 2,177,068 3,073,181 Charles W. Newhall, III 41,743,154 5,492,548 3,073,181”
SUPERNUS PHARMACEUTICALS, INC. incurred debt of approximately $33.4 million with Equiniti Trust Company, LLC.
“On May 17, 2026 (the “Notice Date”), pursuant to the Contingent Value Right Agreement (the “CVR Agreement”) entered into as of July 30, 2025, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent, the Company notified the Rights Agent that Milestone 1, as defined in the CVR Agreement, was achieved on March 18, 2026.”
SUPERNUS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $207.7 million. Guidance reaffirmed.
“Supernus Announces First Quarter 2026 Financial Results • Total revenues were $207.7 million in the first quarter 2026”
SUPERNUS PHARMACEUTICALS, INC. reported financial results for first quarter of 2026.
“On April 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the first quarter of 2026 after the market closes on Tuesday, May 5, 2026.”
SUPERNUS PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Navitor Pharmaceuticals, Inc., Navitor Pharmaceuticals, LLC valued at up to $350 million (effective 2026-04-01).
“On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (“Navitor Parent,” and, together with Navitor, the “Sellers”).”
SUPERNUS PHARMACEUTICALS, INC. amended First Amendment with Reich Consulting Group, Inc. as the Securityholder Representative (effective 2026-01-22).
“On January 22, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into a First Amendment (the “Amendment”) to the Agreement and Plan of Merger dated September 12, 2018 (the “Merger Agreement”), with Reich Consulting Group, Inc. as the Securityholder Representative.”
SUPERNUS PHARMACEUTICALS, INC. completed an acquisition involving Sage Therapeutics, Inc. for approximately $561 million (closed 2025-07-31).
“which is calculated and payable in accordance with the CVR Agreement. The aggregate consideration to be paid by Purchaser to complete the Offer and the Merger is approximately $561 million (exclusive of amounts that may be payable pursuant to the CVRs), without giving effect to related transaction fees and expenses. The foregoing description of the Merger”
SUPERNUS PHARMACEUTICALS, INC.: The Board approved and adopted an updated Code of Ethics and Business Conduct, clarifying reporting channels, consequences for violations, and guidance on conflicts of interest and legal compliance (effective 2024-12-19).
“On December 19, 2024, the Board of Directors of the Company approved and adopted an updated Code of Ethics and Business Conduct (the “Code”).”
SUPERNUS PHARMACEUTICALS, INC. updated its the first quarter of 2024 guidance (reaffirmed).
“On May 8, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release regarding its financial results for the first quarter ended March 31, 2024.”
John M. Siebert retired as Director at SUPERNUS PHARMACEUTICALS, INC..
“On April 22, 2024, John M. Siebert, Ph.D. informed Supernus Pharmaceuticals, Inc. (the “Company”) that he has decided to retire from the Company's Board of Directors (the "Board"), effective at the Company's Annual Meeting of Stockholders in June 2024”
SUPERNUS PHARMACEUTICALS, INC. reported Full year 2023 results: revenue Total revenues (GAAP) of $607.5 million.
“For the full year ended December 31, 2023, total revenues and total net product sales were $607.5 million and $573.9 million”
SUPERNUS PHARMACEUTICALS, INC. reported Fourth quarter 2023 results: revenue Total revenues (GAAP) of $164.3 million.
“For the three months ended December 31, 2023, total revenues and total net product sales (GAAP) were $164.3 million and $156.0 million, respectively”
Roman Bradel was appointed as Vice President, Regulatory Affairs at SUPERNUS PHARMACEUTICALS, INC..
“The Company expects Roman Bradel, Ph.D. to join the Company in March 2024 as its Vice President, Regulatory Affairs reporting to Frank Mottola, the Company’s Senior Vice President, Quality, GMP Operations and IT.”
Tami T. Martin retired as Senior Vice President, Regulatory Affairs at SUPERNUS PHARMACEUTICALS, INC..
“Tami T. Martin, R.N., Esq., the Company’s Senior Vice President, Regulatory Affairs, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of her retirement from the Company effective May 3, 2024.”
SUPERNUS PHARMACEUTICALS, INC. reported financial results for the fourth quarter and full year of 2023.
“Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter and full year of 2023 after the market closes on Tuesday, February 27, 2024.”
SUPERNUS PHARMACEUTICALS, INC. updated its the third quarter ended September 30, 2023 guidance (raised).
“On November 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.”
SUPERNUS PHARMACEUTICALS, INC. reported financial results for the third quarter of 2023.
“Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter of 2023 after the market closes on Wednesday, November 8, 2023.”
Bethany L. Sensenig was appointed as member of the Board of Directors at SUPERNUS PHARMACEUTICALS, INC..
“As of August 17, 2023, the Board of Directors of Supernus Pharmaceuticals, Inc. (the “Company”) appointed Bethany L. Sensenig as a member of the Board of Directors of the Company and as a member of the Audit Committee.”
SUPERNUS PHARMACEUTICALS, INC. reported financial results for the quarter ended June 30, 2023.
“On August 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2023”
SUPERNUS PHARMACEUTICALS, INC. reported the first six months of 2023 results: revenue $289.3 million.
“Total revenues of $289.3 million in the first six months of 2023”
SUPERNUS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $135.5 million.
“expects to have data in the first half of 2024. Financial Highlights Total revenues For the three months ended June 30, 2023, total revenues and total net product sales were $135.5 million and $128.3 million, respectively, compared to total revenues and total net product sales of $170.1 million and $165.5 million for the same periods in 2022. For the six months”
SUPERNUS PHARMACEUTICALS, INC. entered into Settlement and License Agreements with Apotex Inc. and Apotex Corp. (collectively, "Apotex") (effective 2023-06-21).
“On June 21, 2023, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") entered into Settlement and License Agreements (the "Agreements) with Apotex Inc. and Apotex Corp. (collectively, "Apotex"), to settle ongoing patent litigation regarding Apotex's filing of an Abbreviated New Drug Application ("ANDA") seeking approval to market a generic version of the Company's Oxtellar XR ® (oxcarbazepine) extended-release tablets.”
SUPERNUS PHARMACEUTICALS, INC. reported First Quarter 2023 results: revenue 153.8 million, net income 16.9 million, EPS 0.29. Guidance raised.
“Supernus Announces First Quarter 2023 Financial Results • First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 – Qelbree ® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022 – GOCOVRI ® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022 – Excluding net product sales of Trokendi XR ® in both periods, total net product sales increased 25% • First quarter 2023 GAAP operating earnings of $5.2 million, compared to $2.0 million in first quarter 2022 • First quarter 2023 non-GAAP operating earnings of $30.5 million, compared to $28.0 million in first quarter 2022 • Raises full year 2023 GAAP and non-GAAP operating earnings guidance ROCKVILLE, MD, May 9, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for”
SUPERNUS PHARMACEUTICALS, INC. incurred credit facility of $93 million with UBS Bank USA at variable rate.
“On March 30, 2023 the Company borrowed $93 million pursuant to the credit line agreement with UBS Bank USA ("UBS") dated as of February 8, 2023 (the "Credit Line").”
SUPERNUS PHARMACEUTICALS, INC. reported the full year ended December 31, 2022 results: revenue $667.2 million. Guidance initiated.
“Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021”
SUPERNUS PHARMACEUTICALS, INC. updated its the fourth quarter ended December 31, 2022 guidance (initiated).
“On February 28, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.”
SUPERNUS PHARMACEUTICALS, INC. incurred revolving credit of up to $150,000,000.00 with UBS Bank USA at Fixed rate: UBS Fixed Funding Rate + applicable Percentage Spread; Variable rate maturing Not explicitly stated; payable on demand or upon default.
“On February 8, 2023, Supernus Pharmaceuticals, Inc. ( the “Company”) entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”). The Credit Line provides for a revolving line of credit of up to $150,000,000.00, which can be drawn at any time and will be used for general corporate purposes.”
SUPERNUS PHARMACEUTICALS, INC. entered into Credit Line with UBS Bank USA valued at $150,000,000.00 (effective 2023-02-08).
“On February 8, 2023, Supernus Pharmaceuticals, Inc. ( the “Company”) entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”). The Credit Line provides for a revolving line of credit of up to $150,000,000.00”
SUPERNUS PHARMACEUTICALS, INC. updated its third quarter ended September 30, 2022 guidance (raised).
“Supernus Announces Third Quarter 2022 Financial Results • Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 • Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously • Increasing full year 2022 total revenues guidance to $650 million to $680 million, from $640 million to $680 million previously”
Timothy C. Dec was appointed as Senior Vice-President and Chief Financial Officer at SUPERNUS PHARMACEUTICALS, INC..
“On July 27, 2021, the Company appointed Timothy C. Dec to the position of Senior Vice-President and Chief Financial Officer.”
James P. Kelly resigned as Executive Vice-President and Chief Financial Officer at SUPERNUS PHARMACEUTICALS, INC..
“On July 23, 2021, James P. Kelly, Executive Vice-President and Chief Financial Officer, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of his resignation from the Company to join another company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.